Histogenics Corporation to Present at the Canaccord Genuity Growth Conference

WALTHAM, Mass., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13, 2015 at 2:30 PM Eastern Time at the InterContinental Boston, Boston MA.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics'website at www.histogenics.com. The webcast will be available on Histogenics' website for approximately 60 days following the conference.

About Histogenics Corporation

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics' regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics' first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.

CONTACT: Investor Relations
         Tel: +1 (781) 547-7991
         [email protected]

You May Also Be Interested In

• Tesla (TSLA) PT Lowered to $222 at Canaccord Genuity
• Christopher Todd Capital Purchases Arizona BTR Community for $57 Million
• Honda North, Part of an ICL Family of Dealerships, Announces Platinum Sponsorship with Danvers FalconFest